NCT02863250 Australian and New Zealand Massive Transfusion Registry
| NCT ID | NCT02863250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Monash University |
| Condition | Massive Transfusion |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2011-03 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2011-03 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Severe and un-stopped blood loss can occur for a number of different reasons including after a serious injury, delivery of a baby and following other medical and surgical emergencies. The investigators understanding of how to best treat people with serious bleeding is still incomplete, with many questions remaining. These include questions regarding how many people have serious bleeding events, what happens to them and the best way to treat them. The Massive Transfusion Registry (MTR) is a register of patients who have experienced major blood loss that required a massive transfusion in any clinical setting. The MTR uses electronic data extraction and data linkage methodologies. Pre-existing clinical data from hospital data sources, including Laboratory Information Systems (for transfusion history and laboratory results) and Health Information Services databases (for Patient demographics and admission data), are electronically extracted by staff employed at the participating hospitals. The data is then sent to the MTR Research Team, located at Monash University, where it is then linked, analysed and stored. The establishment of a Massive Transfusion Registry will be a unique and important resource for clinicians in Australia, New Zealand and internationally, for Blood Services and for the broader community. It will provide valuable observational data regarding the types and frequency of conditions associated with critical bleeding requiring massive transfusion, the use of blood component therapy (i.e. ratios and quantities of different types of red cell to non- red cell components) and patient outcomes.
Eligibility Criteria
Inclusion Criteria: * aged 18 years or over * 5 or more units of red blood cells in any 4 hour period Exclusion Criteria: * nil
Contact & Investigator
Erica Wood, MBBS
PRINCIPAL INVESTIGATOR
Monash University
Frequently Asked Questions
Who can join the NCT02863250 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Massive Transfusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02863250 currently recruiting?
Yes, NCT02863250 is actively recruiting participants. Contact the research team at sphpm.mtr@monash.edu for enrollment information.
Where is the NCT02863250 trial being conducted?
This trial is being conducted at Melbourne, Australia.
Who is sponsoring the NCT02863250 clinical trial?
NCT02863250 is sponsored by Monash University. The principal investigator is Erica Wood, MBBS at Monash University. The trial plans to enroll 50,000 participants.